Showing results (61-70 of 288) with videos related to

Sort By:
Pageof 29
Urology|December 29, 2009
Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention TrialE David Crawford, Gerald L Andriole, Michael Marberger, et al.
BJU International|July 31, 2007
The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptomsAl Baha Barqawi, Jeremy B Myers, Colin O'Donnell, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 22, 2015
Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dlE David Crawford, Judd W Moul, Oliver Sartor, et al.
Cancer|May 26, 2004
Pathologic evaluation of radical cystectomy specimens: a cooperative group reportHarry W Herr, James R Faulkner, H Barton Grossman, et al.
Oncology (Williston Park, N.Y.)|April 16, 2020
69-Year-Old Man With Castration-Resistant Prostate Cancer Progressing After Docetaxel and Androgen Receptor-Targeting AgentEduardo Gonzalez-Ochoa, Haydee Verduzco-Aguirre, E David Crawford, et al.
Cancer|October 10, 2003
Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinomaL Michael Glode, Albaha Barqawi, Frances Crighton, et al.
Urology|July 28, 2007
Urologists' attitudes regarding cancer clinical researchGregory P Swanson, William R Carpenter, Ian M Thompson, et al.
European Urology|April 11, 2020
"PSA Surveillance in the Septuagenarian": A Proposed New Terminology for Clinical Follow-up to Assess Risk of Prostate Cancer in Men Aged 70 Years and OlderSigrid V Carlsson, James A Eastham, E David Crawford, et al.
Urology|November 20, 2003
Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapyAl Baha Barqawi, Judd W Moul, Ali Ziada, et al.
Urologic Oncology|March 28, 2008
Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancerSeth P Lerner, Catherine M Tangen, Heidi Sucharew, et al.
Pageof 29